Search Results

FDA signage at its headquarters in Maryland

Regulatory

FDA Delays Decision on Merus Bispecific Antibody to Review CMC Information

Despite the PDUFA date being extended by three months for Merus’ zenocutuzumab, Truist Securities analyst Asthika Goonewardene in a Tuesday note to investors said the delay is not a cause for concern with an approval expected.

November 5, 2024

·

2 min read

·

Tristan Manalac

Press Releases

Merus Receives FDA extension of PDUFA for zenocutuzumab

November 5, 2024

·

4 min read

Press Releases

Merus to Present at Upcoming Investor Conferences in November 2024

November 7, 2024

·

1 min read

Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer

Merus N.V. today announced the appointment of Fabian Zohren M.D., PhD as Chief Medical Officer (CMO) effective July 1, 2024.

July 1, 2024

·

6 min read

A scientist with pill bottles in front of FDA headquarters

FDA

FDA Action Alert: Journey, Merus, PTC and Autolus

The FDA is set to decide on four promising therapies in the next two weeks, including a CAR T for acute lymphoblastic leukemia.

November 4, 2024

·

4 min read

·

Tristan Manalac

Genetown

Merus to Participate in a Fireside Chat at the 2024 Jefferies Global Healthcare Conference

Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 11:00 a.m. ET.

May 29, 2024

·

1 min read

Press Releases

Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update

October 31, 2024

·

16 min read

Business

Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update

Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the first quarter and provided a business update.

May 8, 2024

·

18 min read

Genetown

Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting

Merus N.V. announced the publication of an abstract regarding MCLA-145 and an abstract regarding MCLA-129 at the 2024 American Society of Clinical Oncology® Annual Meeting taking place in Chicago May 31-June 4, 2024.

May 23, 2024

·

7 min read

Genetown

Merus N.V. Announces Proposed Public Offering of Common Shares - May 28, 2024

Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced the launch of a proposed underwritten public offering of $300,000,000 of its common shares.

May 28, 2024

·

10 min read